A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Trial Profile

A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 Nov 2017 According to a Bristol-Myers Squibb media release, data of the trial will be present at the 59th Annual Meeting & Exposition of the American Society of Hematology 2017.
    • 17 Apr 2017 Planned End Date changed from 1 Sep 2018 to 31 Dec 2020.
    • 07 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top